ESR1 and breast cancer: Basal-like breast carcinomas, i.e., breast cancers showing triple-negative expression of estrogen receptor, progesterone receptor, and HER2 receptor, are among the most aggressive and deadly cancer subtypes, with a high metastatic ability associated with mesenchymal features [220,221].